Insulin Makers Facing Price Talks Appear Poised to File Lawsuits

Insulin makers whose drugs landed on Medicare’s price negotiations list could be the next to file lawsuits to block the program, even as US officials maintain they’re following the strict requirements of the law when choosing the drugs.

The final drug on Medicare’s top 10 list released Aug. 29 includes three versions each of NovoLog and Fiasp, insulin products made by Novo Nordisk A/S. They accounted for $2.6 billion in total Medicare Part D spending between June 2022 and May 2023, according to agency data.

Six drugmakers, including Merck & Co. and Bristol-Myers Squibb Co., are already challenging ...